Please login to the form below

Not currently logged in
Email:
Password:

treatment

This page shows the latest treatment news and features for those working in and with pharma, biotech and healthcare.

FDA adcomm split on Sanofi’s type 1 diabetes drug

FDA adcomm split on Sanofi’s type 1 diabetes drug

The panel voted eight to eight when asked if the overall benefits of Zynquista (sotagliflozin) outweighed its risks as an add-on to insulin treatment for adult patients with type 1

Latest news

More from news
Approximately 7 fully matching, plus 4,872 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

    In France, 389, 000 people might develop Alzheimer’s dementia while waiting for evaluation and treatment. ... There are also too few facilities with capacity to deliver infusion treatments to patients.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    Mike Thompson, chief executive, ABPI. Having agreed a ceiling on growth, the question of speed of market access for novel treatments will undoubtedly be the key metric preoccupying UK industry leaders ... We called for the rebates from industry to be

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... I-O therapies have the potential to revolutionise cancer treatment and, as of the end of last year, more than 2, 000

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... and a DNA-PK inhibitor, all of which target

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’. ... He added: “Combining therapeutic compounds is the first

More from intelligence
Approximately 2 fully matching, plus 522 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 212 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 20 fully matching, plus 399 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics